Ruthenium-Clotrimazole complex has significant efficacy in the murine model of cutaneous leishmaniasis

Abstract Objectives The current study aimed to evaluate the effects of Ficus carica latex on the treatment of cutaneous leishmaniasis (CL), induced by Leishmania major. A 5% topical gel with F. carica latex was prepared. BALB/c mice were infected by inoculation of amastigotes form of L. major. Thirty BALB/c mice were divided into five groups, where the first group was treated daily, the second group twice per day, and the third group every other day with the 5% topical gel, for 3 weeks. The sizes of the lesions were measured before and during the course of treatment. Results Although the mean size of lesions in the mice group treated with the 5% F. carica gel, especially in the group receiving daily treatment, was less than the mean size of the lesions in the control group, yet, the differences was not statistically significant (p > 0.05). The findings of the current study demonstrated that the 5% F. carica latex with a 3-week course of treatment had no considerable effect in recovery or control of CL induced by L. major in the murine model. Using higher concentration of F. carica latex and with longer treatment lengths may increase its efficacy in the treatment of CL.

Download Full-text

Efficacy of vaccination with a combination of Leishmania amastigote antigens and the lipid A-analogue ONO-4007 for immunoprophylaxis and immunotherapy against Leishmania amazonensis infection in a murine model of New World cutaneous leishmaniasis

Vaccine ◽

10.1016/j.vaccine.2006.03.023 ◽

2006 ◽

Vol 24 (27-28) ◽

pp. 5645-5652 ◽

Cited By ~ 17

Author(s):

Manuel Calvopina ◽

Paola A. Barroso ◽

Jorge D. Marco ◽

Masataka Korenaga ◽

Philip J. Cooper ◽

...

Keyword(s):

Cutaneous Leishmaniasis ◽

Murine Model ◽

New World ◽

Lipid A ◽

Leishmania Amazonensis

Download Full-text

Effect of Prophylactic Vaccination with the Membrane-Bound Acid Phosphatase Gene of Leishmania mexicana in the Murine Model of Localized Cutaneous Leishmaniasis

Journal of Immunology Research ◽

10.1155/2021/6624246 ◽

2021 ◽

Vol 2021 ◽

pp. 1-13

Author(s):

María Angélica Burgos-Reyes ◽

Lidia Baylón-Pacheco ◽

Patricia Espíritu-Gordillo ◽

Silvia Galindo-Gómez ◽

Víctor Tsutsumi ◽

...

Keyword(s):

Cutaneous Leishmaniasis ◽

Murine Model ◽

Clinical Manifestations ◽

Protozoan Parasite ◽

Effective Vaccine ◽

Preventive Strategy ◽

Leishmania Mexicana ◽

T Helper 1 ◽

Lymphoproliferative Response ◽

Prophylactic Vaccination

Leishmaniasis is a disease caused by an intracellular protozoan parasite of the genus Leishmania. Current treatments for leishmaniasis are long, toxic, and expensive and are not available in some endemic regions. Attempts to develop an effective vaccine are feasible, but no vaccine is in active clinical use. In this study, the LmxMBA gene of Leishmania mexicana was selected as a possible vaccine candidate using the reverse vaccinology approach, and the prophylactic effect generated by DNA vaccination with this gene in a murine model of cutaneous leishmaniasis was evaluated. The results showed that prophylactic vaccination with pVAX1::LmxMBA significantly reduced the size of the lesion and the parasitic load on the footpad, compared to the control groups. At a histological level, a smaller number of parasites were evident in the dermis, as well as the absence of connective tissue damage. Mice immunized with plasmid pVAX1::LmxMBA induced immunity characterized by an increase in the IgG 2 a / IgG 1 > 1 ratio and a higher rate of lymphocyte proliferation. In this study, immunization with the plasmid promoted an improvement in the macroscopic and microscopic clinical manifestations of the experimental infection by L. mexicana, with a T helper 1 response characterized by an IgG 2 a / IgG 1 > 1 ratio and high lymphoproliferative response. These findings support immunization with the plasmid pVAX1::LmxMBA as a preventive strategy against cutaneous infection of L. mexicana.

Download Full-text

Clinical Efficacy Associated with Enhanced Antioxidant Enzyme Activities of Silver Nanoparticles Biosynthesized Using Moringa oleifera Leaf Extract, Against Cutaneous Leishmaniasis in a Murine Model of Leishmania major

International Journal of Environmental Research and Public Health ◽

10.3390/ijerph15051037 ◽

2018 ◽

Vol 15 (5) ◽

pp. 1037 ◽

Cited By ~ 21

Author(s):

Manal El-khadragy ◽

Ebtesam Alolayan ◽

Dina Metwally ◽

Mohamed El-Din ◽

Sara Alobud ◽

...

Keyword(s):

Silver Nanoparticles ◽

Cutaneous Leishmaniasis ◽

Antioxidant Enzyme ◽

Clinical Efficacy ◽

Murine Model ◽

Enzyme Activities ◽

Leaf Extract ◽

Moringa Oleifera ◽

Leishmania Major ◽

Antioxidant Enzyme Activities

Download Full-text

WITHDRAWN: Efficacy of vaccination with a combination of Leishmania amastigote antigens and the lipid A-analogue ONO-4007 for immunoprophylaxis and immunotherapy against Leishmania amazonensis infection in a murine model of New World cutaneous leishmaniasis

Vaccine ◽

10.1016/j.vaccine.2006.02.042 ◽

2006 ◽

Author(s):

Manuel Calvopina ◽

Paola A. Barroso ◽

Jorge D. Marco ◽

Masataka Korenaga ◽

Philip J. Cooper ◽

...

Keyword(s):

Cutaneous Leishmaniasis ◽

Murine Model ◽

New World ◽

Lipid A ◽

Leishmania Amazonensis

Download Full-text

Monitoring the efficacy of antimicrobial photodynamic therapy in a murine model of cutaneous leishmaniasis using L. major expressing GFP

Journal of Biophotonics ◽

10.1002/jbio.201000008 ◽

2010 ◽

Vol 3 (5-6) ◽

pp. 328-335 ◽

Cited By ~ 9

Author(s):

Elena Latorre-Esteves ◽

Oleg E. Akilov ◽

Prakash Rai ◽

Stephen M. Beverley ◽

Tayyaba Hasan

Keyword(s):

Photodynamic Therapy ◽

Cutaneous Leishmaniasis ◽

Murine Model ◽

Antimicrobial Photodynamic Therapy

Download Full-text

Antileishmanial Effects of Synthetic EhPIb Analogs Derived from the Entamoeba histolytica Lipopeptidephosphoglycan

Antimicrobial Agents and Chemotherapy ◽

10.1128/aac.00161-20 ◽

2020 ◽

Vol 64 (7) ◽

Cited By ~ 1

Author(s):

Helena Fehling ◽

Siew Ling Choy ◽

Frederic Ting ◽

Dirk Landschulze ◽

Hannah Bernin ◽

...

Keyword(s):

Cutaneous Leishmaniasis ◽

Entamoeba Histolytica ◽

Murine Model ◽

Leishmania Major ◽

Interleukin 4 ◽

Intestinal Protozoan ◽

Cutaneous Lesions ◽

Content Type ◽

Arginase 1

ABSTRACT With an estimated number of new cases annually of approximately 1.4 million, leishmaniasis belongs to the most important parasitic diseases in the world. Nevertheless, existing drugs against leishmaniasis in general have several drawbacks that urgently necessitate new drug development. A glycolipid molecule of the intestinal protozoan parasite Entamoeba histolytica and its synthetic analogs previously showed considerable immunotherapeutic effects against Leishmania major infection. Here, we designed and synthesized a series of new immunostimulatory compounds derived from the phosphatidylinositol b anchor of Entamoeba histolytica (EhPIb) subunit of the native compound and investigated their antileishmanial activity in vitro and in vivo in a murine model of cutaneous leishmaniasis. The new synthetic EhPIb analogs showed almost no toxicity in vitro. Treatment with the analogs significantly decreased the parasite load in murine and human macrophages in vitro. In addition, topical application of the EhPIb analog Eh-1 significantly reduced cutaneous lesions in the murine model, correlating with an increase in the production of selected Th1 cytokines. In addition, we could show in in vitro experiments that treatment with Eh-1 led to a decrease in mRNA expression of arginase-1 (Arg1) and interleukin 4 (IL-4), which are required by the parasites to circumvent their elimination by the immune response. The use of the host-targeting synthetic EhPIb compounds, either alone or in combination therapy with antiparasitic drugs, shows promise for treating cutaneous leishmaniasis and therefore might improve the current unsatisfactory status of chemotherapy against this infectious disease.

Download Full-text